Table 1_Outcomes of low-dose immune tolerance induction with single-dose rituximab in seve

A single-center retrospective cohort study of 16 patients with severe hemophilia A and inhibitors. The dataset describes treatment outcomes, including inhibitor eradication success rates, monthly bleeding rates, and adverse events, for a regimen combining low-dose immune tolerance induction with a single dose of rituximab. The data was authored by Shaoyu Yin and last updated on 2026-04-30.

Use Cases

• Analyzing the success rate of inhibitor eradication based on the reported 68.8% success rate and median time of 9.3 months.
• Evaluating changes in bleeding frequency based on the reported 84.2% reduction in monthly bleeding rate from pre-ITI to during ITI.
• Assessing treatment tolerability based on the reported adverse events, including rituximab-related infusion reactions and fever/pneumonia.
• Comparing clinical outcomes between adult and pediatric patients based on the cohort composition of 8 adults and 8 children.

Strengths

• Includes specific clinical metrics: 68.8% inhibitor eradication success rate and median FVIII recovery of 82%.
• Reports detailed longitudinal data: median monthly bleeding rate decreased from 4 to 0.66 episodes, with a 24-month follow-up for recurrence.
• Describes cohort demographics: 16 patients with a median age of 17 years, split evenly between adults and children.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare, authored by Shaoyu Yin.

Collection Method

Single-center retrospective cohort study.

Freshness

Last updated 2026-04-30 04:21:08; freshness should be verified.